458 related articles for article (PubMed ID: 37859992)
1. Advances in understanding and treating diabetic kidney disease: focus on tubulointerstitial inflammation mechanisms.
Xu C; Ha X; Yang S; Tian X; Jiang H
Front Endocrinol (Lausanne); 2023; 14():1232790. PubMed ID: 37859992
[TBL] [Abstract][Full Text] [Related]
2. What's New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances.
Watanabe K; Sato E; Mishima E; Miyazaki M; Tanaka T
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614011
[TBL] [Abstract][Full Text] [Related]
3. Targeting inflammation to treat diabetic kidney disease: the road to 2030.
Rayego-Mateos S; Rodrigues-Diez RR; Fernandez-Fernandez B; Mora-Fernández C; Marchant V; Donate-Correa J; Navarro-González JF; Ortiz A; Ruiz-Ortega M
Kidney Int; 2023 Feb; 103(2):282-296. PubMed ID: 36470394
[TBL] [Abstract][Full Text] [Related]
4. Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists.
Mende CW; Samarakoon R; Higgins PJ
Am J Nephrol; 2023; 54(1-2):50-61. PubMed ID: 36682353
[TBL] [Abstract][Full Text] [Related]
5. Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease.
Kim DL; Lee SE; Kim NH
Endocrinol Metab (Seoul); 2023 Feb; 38(1):43-55. PubMed ID: 36891650
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic perspective: evolving evidence of nonsteroidal mineralocorticoid receptor antagonists in diabetic kidney disease.
Yao L; Liang X; Wang P
Am J Physiol Endocrinol Metab; 2023 Jun; 324(6):E531-E541. PubMed ID: 37166263
[TBL] [Abstract][Full Text] [Related]
7. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
Lytvyn Y; Godoy LC; Scholtes RA; van Raalte DH; Cherney DZ
Curr Diab Rep; 2019 Jan; 19(1):4. PubMed ID: 30673886
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
Lerma E; White WB; Bakris G
Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
[TBL] [Abstract][Full Text] [Related]
9. Novel pharmacological interventions for diabetic kidney disease.
Tan SK; Pinzon-Cortes JA; Cooper ME
Curr Opin Nephrol Hypertens; 2024 Jan; 33(1):13-25. PubMed ID: 37889557
[TBL] [Abstract][Full Text] [Related]
10. The role of inflammation in diabetic kidney disease.
Jung SW; Moon JY
Korean J Intern Med; 2021 Jul; 36(4):753-766. PubMed ID: 34237822
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases.
Huang W; Chen YY; Li ZQ; He FF; Zhang C
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142794
[TBL] [Abstract][Full Text] [Related]
12. RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.
Koszegi S; Molnar A; Lenart L; Hodrea J; Balogh DB; Lakat T; Szkibinszkij E; Hosszu A; Sparding N; Genovese F; Wagner L; Vannay A; Szabo AJ; Fekete A
J Physiol; 2019 Jan; 597(1):193-209. PubMed ID: 30324679
[TBL] [Abstract][Full Text] [Related]
13. Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes : Lessons from the FIGARO-DKD trial.
Haller H
Herz; 2022 Oct; 47(5):401-409. PubMed ID: 36094559
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms and efficacy of traditional Chinese herb monomers in diabetic kidney disease.
Chen X; Li X; Cao B; Chen X; Zhang K; Han F; Kan C; Zhang J; Sun X; Guo Z
Int Urol Nephrol; 2024 Feb; 56(2):571-582. PubMed ID: 37552392
[TBL] [Abstract][Full Text] [Related]
15. Effects of salt supplementation in uninephrectomized KK-Ay mice: Examining the potential of a diabetic kidney disease model.
Sano R; Ryu K; Sasase T; Shinozaki Y; Teoh SH; Yamaguchi A; Uno K; Maekawa T; Ohta T; Miyajima K
J Toxicol Sci; 2023; 48(11):597-606. PubMed ID: 37914287
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the pharmacotherapeutic management of diabetic kidney disease.
Block TJ; Batu D; Cooper ME
Expert Opin Pharmacother; 2022 May; 23(7):791-803. PubMed ID: 35522659
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets.
Barrera-Chimal J; Jaisser F
Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():16-31. PubMed ID: 32267077
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
[TBL] [Abstract][Full Text] [Related]
19. The Role of Platelets in Diabetic Kidney Disease.
Rustiasari UJ; Roelofs JJ
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955405
[TBL] [Abstract][Full Text] [Related]
20. New strategies to tackle diabetic kidney disease.
Batu Demir D; Cooper ME
Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):348-54. PubMed ID: 27138228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
